Figure 5 | Gene Therapy

Figure 5

From: Ad5/3-9HIF-Δ24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment

Figure 5

Construction of a triple targeted and VEGFR-1-Ig armed oncolytic adenovirus. Schemas of the newly constructed oncolytic viruses Ad5/3-9HIF-Δ24-VEGFR-1-Ig and Ad5/3-9HIF-Δ24-E3 as well as Ad5/3-Δ24, which served as a less specific, unarmed control (a). Kidney cancer cells 786-O (lanes 1–3) and 769-P (lanes 4–6) were infected with Ad5/3-9HIF-Δ24-VEGFR-1-Ig (lanes 1 and 4), Ad5/3-9HIF-Δ24-E3 (lanes 2 and 5) or not infected (lanes 3 and 6) and western blot for secreted VEGFR-1-Ig was performed with supernatants (b). In the Ad5/3-9HIF-Δ24-VEGFR-1-Ig lanes, bands of the expected size (approximately 180 kDa for VEGFR-1-Ig) were detected. The 786-O and SN12L1 kidney cancer cells were infected with 10−4–1000 vp Ad5/3-9HIF-Δ24-VEGFR-1-Ig or Ad5/3-9HIF-Δ24-E3 and cytopathic effect was followed over 10 days (c). Bars, standard error.

Back to article page